BAP1 Genetic Mutation in Mesothelioma Warrants New Treatment Approaches

The University of Hawaii Cancer Center has published novel research on the BAP1 genetic mutation found in an estimated 10% of patients with mesothelioma with the goal of better understanding the unique traits of carriers of the mutation.

Michele Carbone, Director of Thoracic Oncology and lead author of the study published in the Journal of Thoracic Oncology, and his team found that the BAP1 genetic mutation warrants a more personalized methodology focused on preventative care, early detection and different therapeutic approaches compared to mesothelioma not linked to genetic mutations.

According to the study, “Detecting BAP1 germline mutations has, therefore, significant medical, social and economic impact. Close monitoring of these patients and their relatives is expected to result in prolonged life expectancy, improved quality of life and is also cost-effective.”